$AIMT Seems a little overdone considering the competitor is still behind and didn't have comparative placebo data. Keep in mind the initial baseline of tolerance of the DBVT population was more than 2x that of the AIMT participants before the trial began. They were by the study's account, less severe, yet for some reason, this is impacting AIMT greatly. This should be good news for us overall. I did expect some pressure, since I realize people were going to overblow the data, but this is a bit silly to be honest. Oh well, it is a good opportunity for those that are willing to wait for a few days to get a good pop.